VION LICENSES HETEROCYCLIC HYDRAZONES

VION PHARMACEUTICALS, INC. (Nasdaq: VION) announced today that it had entered into an exclusive license agreement with a group of inventors from the Institute of Pharmacy and the Institute of Medical Chemistry and Biochemistry at the University of Innsbruck and Austria Wirtschaftsservice Gesellschaft m.b.H. ("aws"), related to a group of heterocyclic hydrazone compounds covered by patents or patent applications in North America and Europe.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-26-2005/0004131420&EDATE=)